Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation

BACKGROUND: The introduction of adjuvant systemic treatment has significantly improved recurrence-free survival in patients with resectable high-risk melanoma. Adjuvant treatment with immune checkpoint inhibitors and targeted therapy, however, substantially impacts health care budgets, while the num...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulder, E.E.A.P., Smit, L., Grünhagen, D.J., Verhoef, C., Sleijfer, S., van der Veldt, A.A.M., Uyl-de Groot, C.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599106/
https://www.ncbi.nlm.nih.gov/pubmed/34781194
http://dx.doi.org/10.1016/j.esmoop.2021.100303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599106/
https://www.ncbi.nlm.nih.gov/pubmed/34781194
http://dx.doi.org/10.1016/j.esmoop.2021.100303

Ejemplares similares